Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alvotech - Ordinary Shares
(NQ:
ALVO
)
14.51
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alvotech - Ordinary Shares
< Previous
1
2
3
4
Next >
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
May 04, 2023
From
Alvotech
Via
GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
May 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ALVO, ALVOW INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALVOW
May 03, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
May 03, 2023
From
Alvotech
Via
GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
April 19, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
April 19, 2023
From
Alvotech
Via
GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
April 19, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 19, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
April 18, 2023
From
The Schall Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 18, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 18, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Provides Update on Corporate Sustainability Framework
March 28, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 17, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
March 01, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023
From
Alvotech
Via
GlobeNewswire
Settlement of Alvotech Private Share Placement Completed
February 10, 2023
From
Alvotech
Via
GlobeNewswire
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
February 09, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 06, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 24, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Completes $137 Million Private Share Placement
January 23, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
January 13, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
January 11, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
January 06, 2023
From
Alvotech
Via
GlobeNewswire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
December 22, 2022
From
Alvotech
Via
GlobeNewswire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Completes $59.7 Million Private Placement
December 16, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
December 08, 2022
From
Alvotech
Via
GlobeNewswire
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
December 07, 2022
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.